Intravitreal injection of either conbercept or ranibizumab effective in ROP

Intravitreal injection of conbercept or intravitreal injection of ranibizumab are both effective therapies for the treatment of retinopathy of prematurity (ROP), according to a study.

In this prospective, randomized controlled trial 30 infant patients (60 eyes) with ROP received intravitreal injection of conbercept (0.25 mg) and 30 patients (60 eyes) underwent intravitreal injection of ranibizumab (0.25 mg).

Recurrence developed in 16.67% (10 eyes) in the conbercept group and 23.34% (14 eyes) in the ranibizumab group; there was no significant statistical difference in the recurrence rate between the groups.

In the conbercept group and ranibizumab group the postmenstrual age at first injection was 34.60±3.47 weeks and 35.14±1.76, respectively. At second treatment in the recurrent cases, the mean postmenstrual ages were 43.31±3.85 weeks in the conbercept group and 43.43±3.89 weeks in ranibizumab group; there was 8.71±6.62 weeks and 8.29±2.56 weeks between the 2 treatments in each group, respectively. No significant statistical difference between the groups was found.

Reference
Wu Z, Zhao J, Lam W, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. B J Ophthalmol. 2021; DOI: 10.1136/bjophthalmol-2020-318026.